PMID- 24983793
OWN - NLM
STAT- MEDLINE
DCOM- 20141106
LR  - 20220310
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 158
IP  - 4
DP  - 2014 Oct
TI  - Optical coherence tomography-based measurement of drusen load predicts 
      development of advanced age-related macular degeneration.
PG  - 757-761.e1
LID - S0002-9394(14)00382-1 [pii]
LID - 10.1016/j.ajo.2014.06.021 [doi]
AB  - PURPOSE: To determine whether baseline drusen load, as measured using 
      spectral-domain optical coherence tomography (SD OCT), is a useful predictor of 
      development of advanced age-related macular degeneration (AMD). DESIGN: 
      Retrospective cohort study. METHODS: setting: Academic clinical practice. study 
      population: All patients with non-neovascular AMD and no retinal pigment 
      epithelial (RPE) atrophy at baseline who were seen between 2007 and 2012 in a 
      single academic retina practice. A minimum of 1 year of follow-up was required. 
      observation: Drusen load (area and volume) was assessed using automated SD OCT 
      software algorithms. main outcome measure: RPE atrophy area, assessed using an 
      automated SD OCT software algorithm, and the development of neovascular AMD. 
      RESULTS: Eighty-three patients met the inclusion criteria with a mean age of 80 
      years and a mean follow-up time of 2.8 years. Repeated-measures analysis of 
      variance showed an association between drusen area (P = .005) and drusen volume 
      (P = .001) and the development of RPE atrophy. We also found an association 
      between drusen area (P = .001) and drusen volume (P = .001) and the development 
      of neovascular AMD. CONCLUSIONS: Drusen load, as measured using SD OCT, is 
      associated with the development of RPE atrophy and neovascular AMD. SD OCT 
      assessments of drusen load are simple and practical measurements that may be 
      useful in stratifying the risk of developing advanced AMD. These measurements 
      have potential applications in both routine clinical care and clinical trials.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Nathoo, Nawaaz A
AU  - Nathoo NA
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Or, Chris
AU  - Or C
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Young, Mei
AU  - Young M
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Chui, Lica
AU  - Chui L
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Fallah, Nader
AU  - Fallah N
AD  - Rick Hansen Institute, Vancouver, British Columbia, Canada.
FAU - Kirker, Andrew W
AU  - Kirker AW
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Albiani, David A
AU  - Albiani DA
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Merkur, Andrew B
AU  - Merkur AB
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Forooghian, Farzin
AU  - Forooghian F
AD  - Department of Ophthalmology and Visual Sciences, University of British Columbia, 
      Vancouver, British Columbia, Canada. Electronic address: 
      farzin.forooghian@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20140628
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
SB  - IM
MH  - Aged, 80 and over
MH  - Atrophy
MH  - Cohort Studies
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Geographic Atrophy/*diagnosis
MH  - Humans
MH  - Male
MH  - Retinal Drusen/*diagnosis
MH  - Retinal Pigment Epithelium/*pathology
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence/*methods
MH  - Wet Macular Degeneration/*diagnosis
EDAT- 2014/07/02 06:00
MHDA- 2014/11/07 06:00
CRDT- 2014/07/02 06:00
PHST- 2014/03/20 00:00 [received]
PHST- 2014/06/23 00:00 [revised]
PHST- 2014/06/23 00:00 [accepted]
PHST- 2014/07/02 06:00 [entrez]
PHST- 2014/07/02 06:00 [pubmed]
PHST- 2014/11/07 06:00 [medline]
AID - S0002-9394(14)00382-1 [pii]
AID - 10.1016/j.ajo.2014.06.021 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2014 Oct;158(4):757-761.e1. doi: 10.1016/j.ajo.2014.06.021. Epub 
      2014 Jun 28.